Citations

Clear

273 citation(s) found for "Simone, N De".

PHIP- a novel candidate breast cancer susceptibility locus on 6q14.1
Jiao, Xiang , Collaborators, NBCS, Investigators, kConFab/AOCS, Aravidis, Christos , Marikkannu, Rajeshwari, Rantala, Johanna, Adamović, Tatjana , Maguire, Paula , Kremeyer, Bárbara , Holst, Susanna von, Kontham, Vinaykumar, Thutkawkorapin, Jessada , Margolin, Sara , Du, Quan , Lundin, Johanna , Michailidou, Kyriaki , Bolla, Manjeet K. , Wang, Qin , Andrulis, Irene L. , Antonenkova, Natalia, Beckmann, Matthias W. , Blomqvist, Carl , Blot, William J. , Bojesen, Stig E. , Brand, Judith S. , Brauch, Hiltrud , Brenner, Hermann , Brüning, Thomas , Burwinkel, Barbara , Chang‐Claude, Jenny , Couch, Fergus J. , Deming-Halverson, Sandra, Dörk, Thilo , Eriksson, Mikael , Fasching, Peter A. , Figueroa, Jonine D. , Flesch‐Janys, Dieter, Flyger, Henrik, Gabrielson, Marike , García‐Closas, Montserrat , González‐Neira, Anna , Guénel, Pascal , Guo, Qi , Gündert, Melanie , Haiman, Christopher A., Hallberg, Emily, Hamann, Ute , Harrington, Patricia, Hooning, Maartje J. , Hopper, John L. , Huang, Guanmengqian, Jakubowska, Anna , Jones, Michael E. , Kerin, Michael J. , Kosma, Veli‐Matti , Kristensen, Vessela N. , Lambrechts, Diether , Lubiński, Jan , Mannermaa, Arto, Meindl, Alfons, Mulligan, Anna Marie , Peto, Julian, Pylkäs, Katri , Radice, Paolo , Rhenius, Valerie , Sawyer, Elinor J. , Schmutzler, Rita K., Seynaeve, Caroline, Shah, Mitul , Simard, Jacques , Southey, Melissa C. , Swerdlow, Anthony J. , Truong, Thérèse , Wendt, Camilla, Winqvist, Robert , Easton, Douglas F. , Lindblom, Annika , Durocher, Francine , Bowtell, David D.L. , Lambrechts, Diether , Dörk, Thilo , Lambrechts, Diether , Swerdlow, Anthony J , Radice, Paolo , Southey, Melissa C , Jakubowska, Anna , Jones, Michael E , Lambrechts, Diether , Brenner, Hermann , Guénel, Pascal , García-Closas, Montserrat , Michailidou, Kyriaki , Simard, Jacques , Eriksson, Mikael , Figueroa, Jonine D , Gabrielson, Marike , Bowtell, David D , Collaborators, NBCS, Investigators, kConFab/AOCS, Picelli, Simone , Liu, Tao , Luo, Liping , Dennis, Joe , Lush, Michael J. , Ambrosone, Christine B. , Anton‐Culver, Hoda , Arndt, Volker , Boeckx, Bram , Bonanni, Bernardo , Broeks, Annegien , Cai, Qiuyin , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Devilee, Peter , dos‐Santos‐Silva, Isabel , Giles, Graham G. , Hooning, Maartje J. , Marchand, Loı̈c Le , Mannermaa, Arto, Martens, John W.M. , Meindl, Alfons, Milne, Roger L. , Neuhausen, Susan L. , Nevanlinna, Heli , Schmidt, Marjanka K. , Zheng, Wei , Benı́tez, Javier , Dunning, Alison M. , Pharoah, Paul D.P. , Czene, Kamila , Hall, Per N , Pylkäs, Katri , Lubinski, Jan , Bojesen, Stig E , Truong, Therese , Brauch, Hiltrud , Lindblom, Annika , Sawyer, Elinor J

Mayo Clinic

Oncotarget | December 7, 2017 | Volume: 8 | Issue: 61 | Pages: 102769-102782

10.18632/oncotarget.21800 | PMID 29262523 Get It

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
Lewczuk, Piotr , Riederer, Peter , Verbeek, Marcel M. , Dubois, Bruno , Visser, Pieter Jelle , Engelborghs, Sebastiaan , Ramı́rez, Alfredo , Parnetti, Lucilla , Jack, Clifford R. , Teunissen, Charlotte E. , Hampel, Harald , Lleó, Alberto , Jessen, Frank , Glodzik, Lidia , Leon, Mony J. de , Fagan, Anne M. , Molinuevo, José Luís , Jansen, Willemijn J. , Winblad, Bengt , Shaw, Leslie M. , Andréasson, Ulf , Otto, Markus , Mollenhauer, Brit , Wiltfang, Jens , Turner, Martin R. , Zerr, Inga , Handels, Ron , Thompson, Alexander G. , Johansson, Gunilla , Ermann, Natalia, Trojanowski, John Q. , Karaca, Ilker, Wagner, Holger, Oeckl, Patrick , Doorn, Linda van Waalwijk van, Bjerke, Maria , Kapogiannis, Dimitrios , Kuiperij, H. Bea , Farotti, Lucia , Li, Yi , Gordon, Brian A. , Vos, Stephanie J. B. , Klijn, Catharina J.M. , Nostrand, William E. Van , Schmitz, Matthias , Gallo, Carla , Mato, Andrea Lopez, Thibaut, Florence , Lista, Simone , Alcolea, Daniel , Blennow, Kaj , Kornhuber, Johannes , Thibaut, on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence, Verbeek, Marcel M , Ramirez, Alfredo , Parnetti, Lucilla , Jack, Clifford R , Lleó, Alberto , Handels, Ron , Thompson, Alexander G , Trojanowski, John Q , Gordon, Brian A , Thibaut, Florence , Alcolea, Daniel , Kornhuber, Johannes , Teunissen, Charlotte E , Turner, Martin R , Molinuevo, José Luis , O’Bryant, Sid E. , Jellinger, Kurt , Doorn, Linda Josephine Christine van Waalwijk van, Epelbaum, Stéphane , Minguillón, Carolina , Zetterberg, Henrik , Thibaut, on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence, Wiltfang, Jens , Otto, Markus

Mayo Clinic

The World Journal of Biological Psychiatry | October 27, 2017 | Volume: 19 | Issue: 4 | Pages: 244-328

10.1080/15622975.2017.1375556 | PMID 29076399 Get It

Pure arterial malformations
Brinjikji, Waleed , Cloft, Harry J. , Flemming, Kelly D. , Comelli, Simone , Lanzino, Giuseppe , Flemming, Kelly D

Mayo Clinic

Journal of Neurosurgery | September 29, 2017 | Volume: 129 | Issue: 1 | Pages: 91-99

10.3171/2017.2.jns1744 | PMID 28960150 Get It

OBJECTIVEOver the last half century, there have been isolated case reports of purely arterial malformations. In this study, the authors report a consecutive series of patients with pure arterial malformations, emphasizing the clinical and radiological features of these lesions.METHODSPure arterial malformations were defined as dilated, overlapping, and tortuous arteries with a coil-like appearance and/or a mass of arterial loops without any associated venous component. Demographic characteristics of the patients, cardiovascular risk factors, presentation, radiological characteristics, and follow-up data were collected. Primary outcomes were new neurological symptoms including disability, stroke, and hemorrhage.RESULTSTwelve patients meeting the criteria were identified. Ten patients were female (83.3%) and 2 were male (16.6%). Their mean age at diagnosis was 26.2 ± 11.6 years. The most common imaging indication was headache (7 patients [58.3%]). In 3 cases the pure arterial malformation involved the anterior cerebral arteries (25.0%); in 4 cases the posterior communicating artery/posterior cerebral artery (33.3%); in 2 cases the middle cerebral artery (16.6%); and in 1 case each, the superior cerebellar artery, basilar artery/anterior inferior cerebellar artery, and posterior inferior cerebellar artery. The mean maximum diameter of the malformations was 7.2 ± 5.0 mm (range 3–16 mm). Four lesions had focal aneurysms associated with the pure arterial malformation, and 5 were partially calcified. In no cases was there associated intracranial hemorrhage or infarction. One patient underwent treatment for the pure arterial malformation. All 12 patients had follow-up (mean 29 months, median 19 months), and there were no cases of disability, stroke, or hemorrhage.CONCLUSIONSPure arterial malformations are rare lesions that are often detected incidentally and probably have a benign natural history. These lesions can affect any of the intracranial arteries and are likely best managed conservatively.
Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma
Terra, Simone , Mansfield, Aaron S. , Peikert, Tobias, Roden, Anja C. , Terra, Simone B S P, Dong, Haidong , Mansfield, Aaron S , Terra, Simone B S P

Mayo Clinic

OncoImmunology | July 27, 2017 | Volume: 6 | Issue: 11 | Pages: e1356146

10.1080/2162402x.2017.1356146 | PMID 29147606 Get It

Prospective study of proton‐beam radiation therapy for limited‐stage small cell lung cancer
Rwigema, Jean‐Claude M. , Lin, Liyong , Levin, William P., Evans, Tracey L. , Rengan, Ramesh , Langer, Corey J. , Cohen, Roger B. , Simone, Charles B. , Verma, Vivek , Berman, Abigail T. , Aggarwal, Charu , Simone, Charles B , Lin, Liyong

Mayo Clinic

Cancer | July 5, 2017 | Volume: 123 | Issue: 21 | Pages: 4244-4251

10.1002/cncr.30870 | PMID 28678434 Get It

BACKGROUNDExisting data supporting the use of proton‐beam therapy (PBT) for limited‐stage small cell lung cancer (LS‐SCLC) are limited to a single 6‐patient case series. This is the first prospective study to evaluate clinical outcomes and toxicities of PBT for LS‐SCLC.METHODSThis study prospectively analyzed patients with primary, nonrecurrent LS‐SCLC definitively treated with PBT and concurrent chemotherapy from 2011 to 2016. Clinical backup intensity‐modulated radiotherapy (IMRT) plans were generated for each patient and were compared with PBT plans. Outcome measures included local control (LC), recurrence‐free survival (RFS), and overall survival (OS) rates and toxicities.RESULTSThirty consecutive patients were enrolled and evaluated. The median dose was 63.9 cobalt gray equivalents (range, 45‐66.6 cobalt gray equivalents) in 33 to 37 fractions delivered daily (n = 18 [60.0%]) or twice daily (n = 12 [40.0%]). The concurrent chemotherapy was cisplatin/etoposide (n = 21 [70.0%]) or carboplatin/etoposide (n = 9 [30.0%]). In comparison with the backup IMRT plans, PBT allowed statistically significant reductions in the cord, heart, and lung mean doses and the volume receiving at least 5 Gy but not in the esophagus mean dose or the lung volume receiving at least 20 Gy. At a median follow‐up of 14 months, the 1‐/2‐year LC and RFS rates were 85%/69% and 63%/42%, respectively. The median OS was 28.2 months, and the 1‐/2‐year OS rates were 72%/58%. There was 1 case each (3.3%) of grade 3 or higher esophagitis, pneumonitis, anorexia, and pericardial effusion. Grade 2 pneumonitis and esophagitis were seen in 10.0% and 43.3% of patients, respectively.CONCLUSIONSIn the first prospective registry study and largest analysis to date of PBT for LS‐SCLC, PBT was found to be safe with a limited incidence of high‐grade toxicities. Cancer 2017;123:4244–4251. © 2017 American Cancer Society.
Risk of osteoporosis/osteopenia among women with breast cancer receiving anti-cancer therapy (ACT)
Boyce, Simone Peart, Mincey, Betty A., Duh, M.S., Marynchenko, Maryna, Raut, Monika , Brandman, J., Perez, Edith A.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 665-665

10.1200/jco.2005.23.16_suppl.665 Get It

Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic
Lista, Simone , Vanderstichele, Hugo, Posner, Holly, Hall, James , Johnson, Leigh , Fong, Y L, Luthman, Johan, Jeromin, Andreas, Batrla‐Utermann, Richard, Villarreal, Alcibiades E. , Britton, Gabrielle B. , Snyder, Peter J. , Henriksen, Kim , Grammas, Paula , Gupta, Veer Bala , Martins, Ralph N. , Hampel, Harald , Area, Biofluid Based Biomarker Professional Interest, O’Bryant, Sid E. , Mielke, Michelle M. , Rissman, Robert A. , Zetterberg, Henrik , Lewczuk, Piotr , Area, Biofluid Based Biomarker Professional Interest

Mayo Clinic

Alzheimer's & Dementia | November 18, 2016 | Volume: 13 | Issue: 1 | Pages: 45-58

10.1016/j.jalz.2016.09.014 | PMID 27870940 Get It

AbstractThe last decade has seen a substantial increase in research focused on the identification of blood‐based biomarkers that have utility in Alzheimer's disease (AD). Blood‐based biomarkers have significant advantages of being time‐ and cost‐efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood‐based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public‐private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.
Multi‐institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non–small cell lung tumors
Shostrom, Valerie , Kumar, Sameera , Zhen, Weining, Hallemeier, Christopher L. , Holland, John , Harkenrider, Matthew M. , Iskhanian, Adrian S., Neboori, Hanmanth J., Attia, Albert, Lee, Percy , Alite, Fiori , Walker, Joshua M. , Stahl, John M. , Wang, Kyle , Bingham, Brian , Hadzitheodorou, C., Decker, Roy H. , McGarry, Ronald C., Simone, Charles B. , Verma, Vivek , Hallemeier, Christopher Leigh , Braunstein, Steve , Jabbour, Salma K , Simone, Charles B

Mayo Clinic

Cancer | October 14, 2016 | Volume: 123 | Issue: 4 | Pages: 688-696

10.1002/cncr.30375 | PMID 27741355 Get It

BACKGROUNDStereotactic body radiotherapy (SBRT) is the standard of care for patients with nonoperative, early‐stage non–small cell lung cancer (NSCLC) measuring < 5 cm, but its use among patients with tumors measuring ≥5 cm is considerably less defined, with the existing literature limited to small, single‐institution reports. The current multi‐institutional study reported outcomes evaluating the largest such population reported to date.METHODSClinical/treatment characteristics, outcomes, toxicities, and patterns of failure were assessed in patients with primary NSCLC measuring ≥5 cm without evidence of distant/lymph node metastasis who underwent SBRT using ≤5 fractions. Statistics included Kaplan‐Meier survival analyses and univariate/multivariate Cox proportional hazards models.RESULTSA total of 92 patients treated from 2004 through 2016 were analyzed from 12 institutions. The median follow‐up was 12 months (15 months in survivors). The median age and tumor size among the patients were 73 years (range, 50‐95 years) and 5.4 cm (range, 5.0‐7.5 cm), respectively. The median dose/fractionation was 50 Gray/5 fractions. The actuarial local control rates at 1 year and 2 years were 95.7% and 73.2%, respectively. The disease‐free survival rate was 72.1% and 53.5%, respectively, at 1 year and 2 years. The 1‐year and 2‐year disease‐specific survival rates were 95.5% and 78.6%, respectively. The median, 1‐year, and 2‐year overall survival rates were 21.4 months, 76.2%, and 46.4%, respectively. On multivariate analysis, lung cancer history and pre‐SBRT positron emission tomography maximum standardized uptake value were found to be associated with overall survival. Posttreatment failures were most commonly distant (33% of all disease recurrences), followed by local (26%) and those occurring elsewhere in the lung (23%). Three patients had isolated local failures. Grade 3 to 4 toxicities included 1 case (1%) and 4 cases (4%) of grade 3 dermatitis and radiation pneumonitis, respectively (toxicities were graded according to the Common Terminology Criteria for Adverse Events [version 4.0]). Grades 2 to 5 radiation pneumonitis occurred in 11% of patients. One patient with a tumor measuring 7.5 cm and a smoking history of 150 pack‐years died of radiation pneumonitis.CONCLUSIONSThe results of the current study, which is the largest study of patients with NSCLC measuring ≥5 cm reported to date, indicate that SBRT is a safe and efficacious option. Cancer 2017;123:688–696. © 2016 American Cancer Society.